Abstract Number: 686 • 2014 ACR/ARHP Annual Meeting
Clinicians Approaches to the Management of Background Therapy in SLE Patients in Clinical Remission: Results of an International Survey
Background/Purpose: At present there is no consensus on what constitutes a remission in SLE. In particular it is not clear how background therapy should be…Abstract Number: 684 • 2014 ACR/ARHP Annual Meeting
Effects of Current Therapies for Lupus on Disease Activity and Renal Flares
Background/Purpose: A paucity of data exists that delineates the effect of current medications for lupus on disease activity and the propensity for renal flares in…Abstract Number: 683 • 2014 ACR/ARHP Annual Meeting
Impact of Lupus on Work Productivity in Patients and Caregivers: Findings from a Cross-Sectional Online Survey in the United States
Background/Purpose Lupus imposes a substantial burden on patients’ work productivity1; however, little is known about its impact on the work productivity of those caring for…Abstract Number: 682 • 2014 ACR/ARHP Annual Meeting
Impact of Patient’s Priorities on the Management of Systemic Lupus Erythematosus
Background/Purpose: Systemic Lupus Erythematosus (SLE) greatly reduces the quality of life (QoL) and satisfaction with life of affected patients. SLE patients can have numerous unmet…Abstract Number: 679 • 2014 ACR/ARHP Annual Meeting
Hydroxychloroquine Dosing and Disease Activity in a Large Multi-Racial Lupus Cohort
Background/Purpose: Treatment with hydroxychloroquine (HCQ) is recommended for all patients with lupus nephritis to prevent further damage and reduce disease manifestations. Some studies suggest…Abstract Number: 678 • 2014 ACR/ARHP Annual Meeting
The Effectiveness of Tacrolimus for Minor Flares of the Patients with Systemic Lupus Erythematosus
Background/Purpose Although effectiveness of tacrolimus (TAC) for remission induction or maintenance treatment of patients with lupus nephritis has been reported, there are few reports about…Abstract Number: 677 • 2014 ACR/ARHP Annual Meeting
Pharmacokinetics, Safety, and Biological Activity of Intravenously or Subcutaneously Administered Tabalumab in Subjects with Rheumatoid Arthritis or Systemic Lupus Erythematosus
Background/Purpose : B-cell activating factor (BAFF) promotes B-cell survival and maturation, and increased serum levels are associated with autoimmune disease and disease activity in systemic…Abstract Number: 676 • 2014 ACR/ARHP Annual Meeting
Response to Rituximab in Patients with Refractory Systemic Lupus Erythematosus (SLE): Results from a National Multicentre Register
Background/Purpose: Published efficacy data for rituximab in SLE are complex with positive single-centre case series and negative randomised controlled trials. This may be due to…Abstract Number: 675 • 2014 ACR/ARHP Annual Meeting
Use of Rituximab in Systemic Lupus Erythematosus: A Single Center Experience
Background/Purpose Rituximab (RTX), an anti-CD20 chimerical monoclonal antibody, has been used as an off-label in patients with systemic lupus erythematosus (SLE) refractory to standard treatment.…Abstract Number: 674 • 2014 ACR/ARHP Annual Meeting
A Novel Strategy to Identify and Evaluate Approved Drugs and Treatments for Repositioning As Therapies for Systemic Lupus Erythematosus (SLE)
Background/Purpose: Development of new SLE treatments has been slow with only one new treatment approved in the past half century. One way to increase the…Abstract Number: 673 • 2014 ACR/ARHP Annual Meeting
A Comparison of Rheumatoid Arthritis and Systemic Lupus Erythematosus Trial Design: Ways to Improve Positive Trials in Systemic Lupus Erythematosus
Background/Purpose: Recent SLE RCTs were examined and compared to rheumatoid arthritis (RA) RCT to suggest modifications to SLE RCTs that could improve the future success…Abstract Number: 672 • 2014 ACR/ARHP Annual Meeting
Favorable Response to Belimumab in Pediatric-Onset Systemic Lupus Erythematosus
Background/Purpose: Belimumab (Benlysta) is a human monoclonal antibody that inhibits soluble B-lymphocyte stimulator. It was approved by the FDA in 2011 for treatment of active,…Abstract Number: 671 • 2014 ACR/ARHP Annual Meeting
Belimumab Reduces the Frequency of Flares in Patients with Refractory SLE: DATA from Clinical Practice Setting
Background/Purpose To investigate the efficacy and safety of belimumab in patients affected with active systemic lupus erythematosus (SLE) refractory to standard therapy in the clinical…Abstract Number: 670 • 2014 ACR/ARHP Annual Meeting
Decreased Disease Activity and Corticosteroid Usage and No Renal Flares during Belimumab Treatment in Patients with Systemic Lupus Erythematosus
Background/Purpose B cells have a central role in Systemic Lupus Erythematosus (SLE) and autoantibody production. B-Lymphocyte Stimulator (BLyS) is important for the activation and maintenance…Abstract Number: 669 • 2014 ACR/ARHP Annual Meeting
Predicted Chronic Exposure and Dose Selection for Belimumab Administered Subcutaneously to SLE Patients
Background/Purpose: Monthly (q4w) intravenously (IV) administered belimumab 10 mg/kg is approved for the treatment of adults with active, autoantibody-positive SLE receiving standard therapy. The present…
ACR Meeting Abstracts